These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 2197154)

  • 1. Dopamine receptors and transporters in Parkinson's disease and schizophrenia.
    Seeman P; Niznik HB
    FASEB J; 1990 Jul; 4(10):2737-44. PubMed ID: 2197154
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Altropane, a SPECT or PET imaging probe for dopamine neurons: III. Human dopamine transporter in postmortem normal and Parkinson's diseased brain.
    Madras BK; Gracz LM; Fahey MA; Elmaleh D; Meltzer PC; Liang AY; Stopa EG; Babich J; Fischman AJ
    Synapse; 1998 Jun; 29(2):116-27. PubMed ID: 9593102
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human brain D1 and D2 dopamine receptors in schizophrenia, Alzheimer's, Parkinson's, and Huntington's diseases.
    Seeman P; Bzowej NH; Guan HC; Bergeron C; Reynolds GP; Bird ED; Riederer P; Jellinger K; Tourtellotte WW
    Neuropsychopharmacology; 1987 Dec; 1(1):5-15. PubMed ID: 2908095
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [123I]FP-CIT SPECT shows a pronounced decline of striatal dopamine transporter labelling in early and advanced Parkinson's disease.
    Booij J; Tissingh G; Boer GJ; Speelman JD; Stoof JC; Janssen AG; Wolters EC; van Royen EA
    J Neurol Neurosurg Psychiatry; 1997 Feb; 62(2):133-40. PubMed ID: 9048712
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dopaminergic activities in the human striatum: rostrocaudal gradients of uptake sites and of D1 and D2 but not of D3 receptor binding or dopamine.
    Piggott MA; Marshall EF; Thomas N; Lloyd S; Court JA; Jaros E; Costa D; Perry RH; Perry EK
    Neuroscience; 1999 May; 90(2):433-45. PubMed ID: 10215149
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SPECT imaging of pre- and postsynaptic dopaminergic alterations in L-dopa-untreated PD.
    Ichise M; Kim YJ; Ballinger JR; Vines D; Erami SS; Tanaka F; Lang AE
    Neurology; 1999 Apr; 52(6):1206-14. PubMed ID: 10214745
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The dopamine transporter is absent in parkinsonian putamen and reduced in the caudate nucleus.
    Niznik HB; Fogel EF; Fassos FF; Seeman P
    J Neurochem; 1991 Jan; 56(1):192-8. PubMed ID: 1987318
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mesostriatal and mesolimbic dopamine uptake binding sites are reduced in Parkinson's disease and progressive supranuclear palsy: a quantitative autoradiographic study using [3H]mazindol.
    Chinaglia G; Alvarez FJ; Probst A; Palacios JM
    Neuroscience; 1992 Jul; 49(2):317-27. PubMed ID: 1436470
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Receptor and transporter imaging studies in schizophrenia, depression, bulimia and Tourette's disorder--implications for psychopharmacology.
    Kasper S; Tauscher J; Willeit M; Stamenkovic M; Neumeister A; Küfferle B; Barnas C; Stastny J; Praschak-Rieder N; Pezawas L; de Zwaan M; Quiner S; Pirker W; Asenbaum S; Podreka I; Brücke T
    World J Biol Psychiatry; 2002 Jul; 3(3):133-46. PubMed ID: 12478878
    [TBL] [Abstract][Full Text] [Related]  

  • 10. D1 and D2-type dopamine receptors in patients with Parkinson's disease and progressive supranuclear palsy.
    Pierot L; Desnos C; Blin J; Raisman R; Scherman D; Javoy-Agid F; Ruberg M; Agid Y
    J Neurol Sci; 1988 Sep; 86(2-3):291-306. PubMed ID: 2975699
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Striatal dopamine transporter binding in neuroleptic-naive patients with schizophrenia studied with positron emission tomography.
    Laakso A; Vilkman H; Alakare B; Haaparanta M; Bergman J; Solin O; Peurasaari J; Räkköläinen V; Syvälahti E; Hietala J
    Am J Psychiatry; 2000 Feb; 157(2):269-71. PubMed ID: 10671399
    [TBL] [Abstract][Full Text] [Related]  

  • 12. D2 dopamine receptors in neuroleptic-naive schizophrenic patients. A positron emission tomography study with [11C]raclopride.
    Farde L; Wiesel FA; Stone-Elander S; Halldin C; Nordström AL; Hall H; Sedvall G
    Arch Gen Psychiatry; 1990 Mar; 47(3):213-9. PubMed ID: 1968328
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Positron emission tomography reveals elevated D2 dopamine receptors in drug-naive schizophrenics.
    Wong DF; Wagner HN; Tune LE; Dannals RF; Pearlson GD; Links JM; Tamminga CA; Broussolle EP; Ravert HT; Wilson AA; Toung JK; Malat J; Williams JA; O'Tuama LA; Snyder SH; Kuhar MJ; Gjedde A
    Science; 1986 Dec; 234(4783):1558-63. PubMed ID: 2878495
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neurotensin receptors and dopamine transporters: effects of MPTP lesioning and chronic dopaminergic treatments in monkeys.
    Goulet M; Morissette M; Grondin R; Falardeau P; Bédard PJ; Rostène W; Di Paolo T
    Synapse; 1999 Jun; 32(3):153-64. PubMed ID: 10340626
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Test/retest reproducibility of iodine-123-betaCIT SPECT brain measurement of dopamine transporters in Parkinson's patients.
    Seibyl JP; Marek K; Sheff K; Baldwin RM; Zoghbi S; Zea-Ponce Y; Charney DS; van Dyck CH; Hoffer PB; Innis RB
    J Nucl Med; 1997 Sep; 38(9):1453-9. PubMed ID: 9293807
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Voxel-wise analysis of [123I]beta-CIT SPECT differentiates the Parkinson variant of multiple system atrophy from idiopathic Parkinson's disease.
    Scherfler C; Seppi K; Donnemiller E; Goebel G; Brenneis C; Virgolini I; Wenning GK; Poewe W
    Brain; 2005 Jul; 128(Pt 7):1605-12. PubMed ID: 15817519
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Single photon emission computed tomography imaging of dopaminergic function: presynaptic transporter, postsynaptic receptor, and "intrasynaptic" transmitter.
    Innis RB
    Adv Pharmacol; 1998; 42():215-9. PubMed ID: 9327882
    [No Abstract]   [Full Text] [Related]  

  • 18. Changes in dopamine availability in the nigrostriatal and mesocortical dopaminergic systems by gait in Parkinson's disease.
    Ouchi Y; Kanno T; Okada H; Yoshikawa E; Futatsubashi M; Nobezawa S; Torizuka T; Tanaka K
    Brain; 2001 Apr; 124(Pt 4):784-92. PubMed ID: 11287377
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Loss of dopamine uptake sites and dopamine D2 receptors in striatonigral degeneration.
    González AM; Berciano J; Figols J; Pazos A; Pascual J
    Brain Res; 2000 Jan; 852(1):228-32. PubMed ID: 10661519
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rapid detection of Parkinson's disease by SPECT with altropane: a selective ligand for dopamine transporters.
    Fischman AJ; Bonab AA; Babich JW; Palmer EP; Alpert NM; Elmaleh DR; Callahan RJ; Barrow SA; Graham W; Meltzer PC; Hanson RN; Madras BK
    Synapse; 1998 Jun; 29(2):128-41. PubMed ID: 9593103
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.